Velocity Clinical Research acquired by GHO signalling evolution of clinical trial site industry
News provided by
Share this article
Share this article
DURHAM, N.C., April 8, 2021 /PRNewswire/ -- Leading integrated clinical trial site organisation, Velocity Clinical Research ("Velocity"), today announces it has entered into an agreement with Global Healthcare Opportunities, or GHO Capital ("GHO"), the European specialist investor in healthcare, to be acquired from NaviMed Capital ("NaviMed") and other investors, signalling how the business of running clinical trial sites is changing.
Headquartered in Durham, North Carolina, Velocity operates 16 fully-owned sites across 11 US states. The company serves biopharmaceutical and contract research organisation (CRO) clients in primarily conducting phase II and phase III clinical trials in support of their global drug development programs. In just three years, Velocity has worked with over 200 biopharmaceutical clients, including all of the top 10 pharma sponsors, and its sites have collectively conducted over 5,000 clinical trials.